To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approxi...To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approximately 20 to 25 mg tr iamcinolone acetonide for treatment of diabetic macular edema (n=6 eyes), exudat ive age-related macular degeneration (n=23), and other diseases. Intervals betw een injections were 6.7 ±3.4 months, 8.0 ±4.6 months, and 10.2 months, respect ively, before the second (n=47 eyes), third (n=9), and fourth (n=2) injection. M ean follow-up was 20.7±8.9 months. After no reinjection were complications det ected, other than those known to occur after a single intravitreal injection. Af ter the first, second, and third injection, respectively, intraocular pressure r emained normal in 24 (51%), 25 (53%), and 26(56%)eyes. Intravitreal high-dos age reinjections of triamcinolone acetonide may be tolerated within a mean follo w-up of approximately 21 months.展开更多
文摘To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approximately 20 to 25 mg tr iamcinolone acetonide for treatment of diabetic macular edema (n=6 eyes), exudat ive age-related macular degeneration (n=23), and other diseases. Intervals betw een injections were 6.7 ±3.4 months, 8.0 ±4.6 months, and 10.2 months, respect ively, before the second (n=47 eyes), third (n=9), and fourth (n=2) injection. M ean follow-up was 20.7±8.9 months. After no reinjection were complications det ected, other than those known to occur after a single intravitreal injection. Af ter the first, second, and third injection, respectively, intraocular pressure r emained normal in 24 (51%), 25 (53%), and 26(56%)eyes. Intravitreal high-dos age reinjections of triamcinolone acetonide may be tolerated within a mean follo w-up of approximately 21 months.
